Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030118 · ClinicalTrials.gov registry record · Phase 2
Study of Anti-Malarials in Incomplete Lupus Erythematosus
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
NCT03030118 is a Phase 2 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 187 participants.
The verdict
NCT03030118, a Phase 2 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
Study Summary
This project is a multicenter, randomized, placebo-controlled, double-blind clinical trial that is designed to test whether treating patients who are at risk for development of lupus with hydroxychloroquine can slow accumulation of disease features. Effects on clinical progression of symptoms, patient-reported outcomes and changes in the immune markers of response will be measured and toxicity of the treatment will be assessed. This trial is a first step in testing a prevention strategy for lupus.
Interventions
- DRUG Placebo Oral Capsule
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2017-12-28 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03030118
The ClinicalTrials.gov registry entry for NCT03030118 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Capsule is the first listed.
NCT03030118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03030118 about?
NCT03030118 is a clinical study titled "Study of Anti-Malarials in Incomplete Lupus Erythematosus". This project is a multicenter, randomized, placebo-controlled, double-blind clinical trial that is designed to test whether treating patients who are at risk for development of lupus with hydroxychloroquine can slow accumulation of disease features. Effects on clinical progression of symptoms, patie...
What is the current status of trial NCT03030118?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2017-12-28. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT03030118?
The interventions under investigation include: Placebo Oral Capsule (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT03030118?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.